Technical Analysis for XRTX - Xortx Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 1.39% | |
| Wide Bands | Range Expansion | 1.39% | |
| Oversold Stochastic | Weakness | 1.39% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 17 hours ago |
| Gapped Up (Full) | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Rose Above 10 DMA | about 22 hours ago |
| Up 1 ATR | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 2024-05-15
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.35 |
| 52 Week Low | 0.33 |
| Average Volume | 18,244 |
| 200-Day Moving Average | 2.623 |
| 50-Day Moving Average | 4.956 |
| 20-Day Moving Average | 4.032 |
| 10-Day Moving Average | 3.657 |
| Average True Range | 0.341 |
| RSI (14) | 40.48 |
| ADX | 18.85 |
| +DI | 30.777 |
| -DI | 27.615 |
| Chandelier Exit (Long, 3 ATRs) | 4.297 |
| Chandelier Exit (Short, 3 ATRs) | 4.423 |
| Upper Bollinger Bands | 4.987 |
| Lower Bollinger Band | 3.078 |
| Percent B (%b) | 0.3 |
| BandWidth | 47.346 |
| MACD Line | -0.365 |
| MACD Signal Line | -0.356 |
| MACD Histogram | -0.009 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.325 | ||||
| Resistance 3 (R3) | 4.400 | 4.250 | 4.213 | ||
| Resistance 2 (R2) | 4.250 | 4.078 | 4.213 | 4.175 | |
| Resistance 1 (R1) | 3.950 | 3.972 | 3.875 | 3.875 | 4.137 |
| Pivot Point | 3.800 | 3.800 | 3.763 | 3.763 | 3.800 |
| Support 1 (S1) | 3.500 | 3.628 | 3.425 | 3.425 | 3.163 |
| Support 2 (S2) | 3.350 | 3.522 | 3.313 | 3.125 | |
| Support 3 (S3) | 3.050 | 3.350 | 3.088 | ||
| Support 4 (S4) | 2.975 |
